For additional safety information, see accompanying Brief Summary of Safety Information
on the adjacent page and Full Prescribing Information on Xiidra-ECP.com.
Marks designated
®
and
™
are owned by Shire or an affi liated company.
©2016 Shire US Inc. Lexington, MA 02421 S24432 11/16
The fi rst prescription eye drop FDA-approved to treat
both the signs and symptoms of Dry Eye Disease
OHH, IINTERESTING
Indication
Xiidra
®
(lifi tegrast ophthalmic solution) 5% is indicated for the treatment
of signs and symptoms of dry eye disease (DED).
Important Safety Information
In clinical trials, the most common adverse reactions reported in 5-25%
of patients were instillation site irritation, dysgeusia and reduced visual
acuity. Other adverse reactions reported in 1% to 5% of the patients
were blurred vision, conjunctival hyperemia, eye irritation, headache,
increased lacrimation, eye discharge, eye discomfort, eye pruritus
and sinusitis.
To avoid the potential for eye injury or contamination of the solution,
patients should not touch the tip of the single-use container to their
eye or to any surface.
Contact lenses should be removed prior to the administration of
Xiidra and may be reinserted 15 minutes following administration.
Safety and effi cacy in pediatric patients below the age of 17 years
have not been established.
Reference: 1. FDA approves new medication for
dry eye disease. FDA News Release. July 2016.
http://www.fda.gov/newsevents/newsroom/
pressannouncements/ucm510720.htm. Accessed
July 12, 2016.
Xiidra is a lymphocyte
function-associated antigen-1
(LFA-1) antagonist, the fi rst
medication in a new class
of drugs.
1
Check it out at Xiidra-ECP.com
